(G.N.S) Dt. 23 New Delhi Emergency use for Zydus Cadila’s Pegylated Interferon alpha-2b has got an approval from Drugs Controller General of India (DCGI). Virafin’ for the treatment of moderate Covid-19 infection in adults. In a statement, the company informed, “PegIFN in COVID-19 has several add-on advantages compared to other anti-viral agents. The treatment regimen would be less cumbersome and more affordable for patients as Pegylated Interferon Alpha 2b, is a single
This content is restricted to site members. If you are an existing user, please log in. New users may register below.